Iron is an essential metal element for human body. It is involved in many important biological metabolic processes. Iron metabolism in the central nervous system has a strict regulatory mechanism. Iron deposition occurs when the homeostasis of iron metabolism is disrupted, leading to an increase in neuronal iron uptake and a decrease in iron discharge. Aging cells develop specific iron deposition, and excessive iron produce reactive oxygen species, which can damage DNA. Highly reactive aldehydes result in irreversible modification of proteins. Stored proteins were stimulated to release iron, which in turn produces more reactive oxygen species, ultimately leading to iron-mediated cell death and neurological dysfunction. The widely used methods for assessing iron deposition include susceptibility weighted imaging and quantitative susceptibility mapping. Abnormally elevated brain iron deposition has been observed in a variety of central nervous system diseases, especially in Parkinson disease. Iron deposition plays an important role in early diagnosis, differential diagnosis, disease evaluation and monitoring and therapeutic effect evaluation of Parkinson disease. This article reviews the research progress of iron deposition in Parkinson disease.

Colorectal cancer has been one of the leading malignancies with a high incidence and a great mortality in the world, Liver is the most common site of metastases.For nonresectable colorectal liver metastases(nrCRLM), no palliative therapy brings any change of terminal death.With limited sample sizes but long enough follow-ups, a series of clinical trials have confirmed that selected nrCRLM patients may be cured by liver transplantation(LT). However, there are great challenges of donor shortage, recipient criteria and high recurrence rate after LT.For promoting the curative effect and quality control, the authors elaborated upon various major issues of LT for nrCRLM, including non-resectability of colorectal liver metastases, chemotherapy-associated liver injuries, prognostic factors, surgical approaches and post-transplant therapies.

Objective: To detect the altered levels of miR-422a in serum of traumatic brain injury (TBI) patients and explore its clinical value as diagnostic and prognostic indicator for TBI. Methods: Serum miR-422a levels were determined by TaqMan quantitative real-time polymerase chain reaction (qRT-PCR) in 75 mild traumatic brain injury (mTBI) patients, 75 severe traumatic brain injury (sTBI) patients and 75 healthy controls. The differences of serum miR-422a levels were compared between the TBI patients with and without lesions on head CT. Receiver operating characteristic (ROC) curve analyses were used to evaluate the diagnostic efficacy of miR-422a for mTBI and sTBI patients. Spearman correlation analysis was used to assess the relationship between the levels of miR-422a and the severity and prognosis of TBI patients. Results: Compared with healthy controls [(31.1×10 -5 (18×10 -5 , 51.5×10 -5 )］, the serum miR-422a level was significantly increased in both the patients of mTBI 81.6×10 -5 (51.2×10 -5 , 131.1×10 -5 ) (Z=-6.647, P＜0.001)］and sTBI [132.5×10 -5 (51.5×10 -5 , 240.5×10 -5 ) (Z=-7.345, P＜0.001)］. The serum miR-422a level of sTBI patients was significantly higher than that of mTBI patients (Z=-2.573, P=0.01). The area under ROC curve (AUC ROC ) of miR-422a for distinguishing healthy controls from TBI patients was 0.831 (95%CI: 0.776 to 0.886, P＜0.001). The AUC ROC of miR-422a for distinguishing healthy controls from mTBI patients was 0.814 (95%CI: 0.744 to 0.885, P＜0.001). The AUC ROC of miR-422a for distinguishing healthy controls from sTBI patients was 0.847 (95%CI: 0.785 to 0.910, P＜0.001). miR-422a level of the TBI patients with lesions on head CT were significantly increased compared with that without lesions on head CT (P=0.025). In addition, the level of miR-422a in TBI patients with unfavorable outcome was significantly higher than that in TBI patients with favorable outcome (P=0.031). Spearman correlations analysis showed that the level of the miR-422a was significantly negatively correlated with GCS score (Glasgow coma scale) (r=-0.231, P=0.004) and GOS score (Glasgow outcome scale) (r=-0.208, P=0.011). Conclusion The level of serum miR-422a in TBI patients was significantly increased and related to the condition and prognosis of TBI patients. Serum miR-422a may be a potential biomarker for the assessment of diagnosis and prognosis of TBI patients.

The residual cardiovascular disease (CVD) risk is the term applied to the cardiovascular events remain prevalent among individuals with low or normal LDL-C, normal blood pressure and glucose. Therefore, while controlling traditional risk factors, the CVD residual risk is constantly being discovered, which is crucial for further reducing CVD events. Lipoprotein (a), TRLs and their residues, HDL-C, hypersensitive CRP and homocysteine have been found to be CVD residual risk factors. Whether gene-related factors and some new non-traditional factors can predict residual CVD risk have also become the current research hotspots. Focusing on the residual risk factors of cardiovascular disease can provide new ideas for further reducing CVD events.

Dyslipidemia is one of the important risk factors for cardiovascular and cerebrovascular diseases.Extensive evidence has proven that effective control of dyslipidemia can reduce the incidence and mortality of cardiovascular and cerebrovascular diseases .In recent years, related research in the field of blood lipids has been quite active.The guidelines for the management of dyslipidemia in Europe , the United States, and China have been successively updated .Although there are some disagreements on whether the LDL-C should reach the target value and whether blood lipid testing needs fasting , all of these new guidelines emphasize the importance of controlling blood lipid levels in different risk stratification groups , also emphasize that lipid-lowering therapy should be patient-centered to improve patient compliance .At present, most of the laboratory report of blood lipid test results in China cannot meet the requirements of different therapeutic targets for patients with different risk groups in the " Guidelines for the management of blood lipids".How to make the reasonable blood lipid reference range better reflected in the clinical test report form, is also one of the directions that future laboratory physicians need to work hard on.

Objective To detect altered levels and clinical significance of serum miR-216a and prognosis monitoring in acute pancreatitis (AP) patients.Methods Serum miR-216a levels were determined by quantitative reverse-transcription PCR (qRT-PCR) assay among 80 mild acute pancreatitis (MAP) patients,80 severe acute pancreatitis (SAP) patients and 74 healthy controls.And amylase (AMY),lipase (LPS),Ca2+,glucose (Glu),hematocrit (HCT),triglyceride (TG),total cholesterol (TC) and C reactive protein (CRP) were measured by biochemical analyzer.The clinical usefulness of miR-216a for AP patients was assessed by ROC curve analysis and correlation analysis.Results Compared with healthy controls (11.12 × 10-5 [5.83 × 10-5,19.12 × 10-5],the serum miR216a levels were significantly increased in AP patients(38.49 × 10-5 [24.05 × 10-5,62.02 × 10-5],(U =-9.10,P ＜ 0.01) . The serum miR-216a levels in MAP and SAP patients were (36.46 × 10-5 [22.29 × 10-5,55.80 × 10-5] vs 40.44 × 10-5 [25.84 × 10-5,65.48 × 10-5]),there was no significant difference between MAP and SAP patients (U =-0.96,P ＞ 0.05).The areas under ROC curve (AUCROC) of miR-216a for differential healthy controls and AP patients was 0.870 (95％ CI:0.825-0.915),cut-off value is 0.61.AUCROC of miR-216a for differential healthy controls and MAP patients was 0.865 (95％ CI:0.808-0.921),cut-off value is 0.59.And AUCROC of miR-216a for differential healthy controls and SAP patients was 0.876 (95％ CI:0.822-0.930),cut-off value is 0.66.Moreover,after the clinical improvement of the patients,the levels of serum miR-216a were significantly lowered from (41.88 × 10-5 [24.24 × 10-s,64.44 × 10-5]) to (20.58 × 10-5 [11.01 × 10-5,41.91 × 10-5]),the differences was significant(U =5.24,P ＜ 0.0l).Correlation analysis showed that miR-216a was positively correlated with CRP (r =0.215,P =0.006) in AP patients.Conclusion The levels of miR-216a in serum of AP patients were increased,which is a potential biomarker for the diagnosis and prognosis monitoring of AP.

Objective To analyze serum levels of C1q in children with nephrotic syndrome (NS),and investigate the clinical significance and the relationship among the altered serum C1q levels and other lipid/lipoprotein and renal function parametersin children with NS inacute and remission phases.Methods Serum levels of C1q were measured in 78 NS children with acute phase,in 64NS children with remission and in 77 healthy control children.The other lipid/lipoprotein and renal function parameters were also analyzed in these children,including TP,ALB,TC,TG,LDL-C,HDL-C,Urea,Cr and Uric.Results Compared with the healthy control children [173.00(161.00～185.00)mg/L],children with NS inacute [203.50(183.75 ～ 223.75) mg/L] and remission phases [185.00 (161.00 ～ 202.00) mg/L] all had a significantly increasedserum levels of C1q.Compared with NS children in remission,those in acute phase showed a significantly increased C1q (P＜0.001).In all the NS children,the serum levels of C1q were positively correlated with the levels of TC (r=0.483,P＜0.001),TG (r=0.423,P＜0.001) and LDL-C (r=0.450,P＜0.001),while negatively correlated with the levels of TP (r=-0.276,P=0.001 ＜0.01) and ALB (r=-0.410,P＜0.001).Multiple linear regression analyses showed that serum levels of C1q were independently associated with serum TG levels (β=9.235,P＜0.001;adjusted R2 =0.215) after adjustment of other related factors.Conclusion Serum levels of C1q were significantly increased in NS children in association with their conditions and the levels of lipid/lipoprotein parameters,and may be function as anovel parameter for assessing the development of NS.

Objective To analyze the changes of serum levels ofαII-spectrin breakdown products (SBDPs)in traumatic brain inj ury (TBI)patients,and further to investigate the clinical diagnosis value of SBDPs for patients with TBI,especially with mTBI.Methods The serum levels of SBDPs were examined in 43 severe TBI (sTBI)patients,43 mild TBI (mTBI)patients and 43 healthy controls using enzyme linked immunosorbent assay (ELISA).The diagnostic usefulness of SBDPs for TBI patients were assessed by Receiver Operating Characteristic (ROC)curves analysis.Results There was no significant difference of SBDP145 among the three groups (F=1.340,P>0.05).Serum levels of SBDP120 in controls,mTBI and con-trols were 7.06±2.23,11.67±9.14 and 12.64±11.44 ng/ml,respectively.Compared with controls,serum levels of SB-DP120 were significantly higher in patients with sTBI (F=9.873,P=0.001)and mTBI (F=9.873,P=0.008),while there was no significant difference of SBDP120 between sTBI patients and mTBI patients (F=9.873,P=0.515>0.05). The area under ROC curve (AUC)of SBDP120 for TBI patients was 0.781 (95% CI:0.690~0.872,P<0.001).For mTBI patients,the area under ROC curve was 0.736 (95% CI:0.624~0.848,P<0.001).And for discriminating TBI patients with CT negative or positive,the area under ROC curve was 0.709 (95% CI:0.582~0.837,P=0.007<0.01).Conclusion The serum levels of SBDP120 were significantly increased in TBI patients,especially mTBI patients.And the serum levels of SBDP120 can be used as potential non-invasive biomarker for mTBI patients.

Objective To observe the inhibitory effect of quercetin on the biofilm formation of Streptococcus mutans(Sm),to preliminarily reveal the possible underlying mechanisms,and to evaluate the cytotoxicity of quercetion to human dental pulp cells so as to provide the theoretical basis for the application of quercetin in oral biomaterials.Methods Quercetin storage solution was diluted to 0,3.125,6.25,12.5,25,50,100,200,400 and 800 mg/L,and added into Sm medium for 4 h and 24 h,crystal violet staining was used to evaluate the biofilm volume.In subsequent detections,three groups were set:control(0 mg/L),200 mg/L quercetin and 400 mg/L quercetin.Confocal laser scanning microscopy was used to observe the morphology of the biofilm;qPCR for gtfB,gtfC,comD,comE,and luxS were assessed to preliminarily investigate the mechanisms.Finally,the methyl thiazolyl tetrazolium(MTT) test using human dental pulp cells was used to investigate cytotoxicity.Results Quercetin could significantly inhibit up to (86.16±0.45)％ of the biofilm formation of Sm (Compared with the control group P=0.00) and effectively removed (43.04±0.53)％ of the mature biofilm(Compared with the control group P=0.00).Confocal laser scanning microscopy photographs showed that after co-incubated for 24 h,the dense biofilm structures of the experimental group were destroyed by quercetin both at 200 mg/L and 400 mg/L.Quercetin suppressedover 50％ of the expression of gtfB,gtfC,comD,comE(compared with the control group P＜0.05) and promoted the expression of luxS up to 2.18 ±0.24 and 2.84±0.26 after 4 h and 24 h,respectively(compared with the control group P＜0.05).Quercetin also exhibited acceptable compatibility for human dental pulp cells.Conclusions Quercetin could effectively reduce the biofilm formation of Sm by inhibiting the expression of the related genes,and exhibited no cytotoxicity for human dental pulp cells.Quercetin has good potential to be applied in oral biological materials.

Central nervous system ( CNS) injuries, such as cerebral ischemia, traumatic brain injury (TBI), and spinal cord injury (SCI), are often accompanied by complex pathological changes, and could lead to a variety of other neurological diseases.Neurons and glial cells are precisely regulated by many genes.MicroRNA ( miRNA ) are endogenous molecules discovered in recent years that regulate post transcriptional gene expression.They are highly expressed in the central nervous system and abnormal expressed under pathological conditions.They are involved in regulating variety of pathological processes after CNS injuries, and are CNS disease potential biomarkers.